ArticleHuman genome variation2025
Distribution of CCR5-Δ32 and HLA-B*57:01 alleles in HIV-seropositive and HIV-exposed seronegative Peruvian individuals.
Article in Human genome variation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Little information is available about CCR5-Δ32 and HLA-B*57:01 alleles in the Peruvian population, especially in human immunodeficiency virus (HIV)-negative people with high-risk sexual behavior. Here we describe the prevalence of these alleles in HIV-exposed seronegative individuals (PS) and HIV-seropositive individuals (PVV). For this purpose, 300 individuals were recruited: 150 from each group, and the selected alleles were characterized by endpoint PCR, real-time PCR and DNA sequencing. According to our results, the prevalence of CCR5/CCR5-Δ32 heterozygous was 2.7%, and no homozygous cases were found. The population was in Hardy-Weinberg equilibrium for the CCR5 locus. Regarding HLA-B*57:01, one case was identified in the PS group, while no cases were observed in the PVV group. No statistical difference was detected between groups (P > 0.05). In conclusion, we showed a low prevalence for CCR5-Δ32 as HLA-B*57:01 in the Peruvian population. As these alleles were found at similar frequencies among both HIV-positive and HIV-negative Peruvian individuals with high-risk sexual behavior, it is possible that other genetic factors play an important role in preventing HIV transmission in this population. The low frequency of the HLA-B*57:01 allele in the Peruvian population suggests that routine genotyping tests for abacavir hypersensitivity should be reevaluated in the public health policies of Peru's Ministry of Health, based on national epidemiological data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.